Renalytix Plc (RNLX)
|52 Week Range||1.05-4.038|
|1y Target Est||-|
|DCF Unlevered||RNLX DCF ->|
|DCF Levered||RNLX LDCF ->|
|Debt / Equity||173.95%||Buy|
Upgrades & Downgrades
Latest RNLX news
Renalytix surges 28% Medicaid news
3 October 2023
Shares of Renalytix PLC (AIM:RENX) surged 28% in early trading after the Centers for Medicare & Medicaid Services (CMS) announced a price of $950 for the company's FDA-approved kidneyintelX.dkd test. ...
Renalytix Plc (RNLX) Q4 2023 Earnings Call Transcript
29 September 2023
Renalytix Plc (NASDAQ:RNLX ) Q4 2023 Earnings Conference Call September 28, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Thomas McLa...
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
25 September 2023
LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September...
Renalytix jumps on Middle East distribution deal, 'region with most diabetes globally'
21 July 2023
Renalytix PLC (AIM:RENX) shares ramped 7.5% higher to 128.95p on Friday morning after it announced a distribution agreement for its kidneyintelX.dkd with Vector Pharma for the Middle East, a region th...
Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool
16 July 2023
Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval and established insurance reimbursement, partnerships, and a sales team. The KidneyIntelX pl...
Why Is Renalytix (RNLX) Stock Up 45% Today?
30 June 2023
Renalytix (NASDAQ: RNLX ) stock is rising higher on Friday after the medical company got marketing permission from the FDA. According to a press release from Renalytix, the FDA is allowing the company...
Renalytix Plc (RNLX) Q2 2023 Earnings Call Transcript
30 March 2023
Renalytix Plc (NASDAQ:RNLX ) Q2 2023 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - CEO O. James Sterling - CFO Thomas McLa...
Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
22 March 2023
LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial ...
Renalytix: More Progress But Still Risky
1 March 2023
Renalytix has been fundraising successfully, extending its runway. Sales growth is strong albeit from a tiny base. Dozens of provider contracts are now in place across the U.S., though.